The facility, which was supported by the Singapore Economic Development Board, will include a high-speed sterile line approved for live virus filling and an additional line for standard filling and finishing. When it opens in 2022, it also will have cleanroom capacity, labs, warehousing, and offices to support production. The facility is expected to manufacture up to 30 million sterile doses per month, according to the company.
The facility is being built to meet pharmaceutical product demand in the Asia-Pacific region and to respond more effectively to future health emergencies, like COVID-19.
Copyright © 2020 scienceboard.net